Heron Therapeutics (HRTX) Treasury Shares (2020 - 2026)

Heron Therapeutics has reported Treasury Shares for 7 years, with the latest figure at $11.3 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares rose 194.39% year-over-year to $11.3 million; the trailing twelve-month figure through Mar 2026 stood at $11.3 million (up 194.39% YoY), and the FY2025 full-year result was $3.8 million, up 91.77% from the prior year.
• Treasury Shares for Q1 2026 stood at $11.3 million, up from $3.8 million in the prior quarter.
• The five-year high for Treasury Shares was $1.8 billion in Q3 2023, with the low at $1.4 million in Q4 2023.
• Historically, Treasury Shares has averaged $108.2 million across 5 years, with a median of $2.8 million in 2022.
• Annual changes were most pronounced in 2023 — Treasury Shares soared 63301.53% — and 2024, when it tumbled 99.91%.
• Heron Therapeutics' Treasury Shares stood at $3.2 million in 2022, then tumbled by 55.64% to $1.4 million in 2023, then soared by 41.0% to $2.0 million in 2024, then surged by 91.77% to $3.8 million in 2025, then jumped by 198.5% to $11.3 million in 2026.
• The last three Treasury Shares figures came in at $11.3 million (Q1 2026), $3.8 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.